Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock

(NYSE:CMRE),(NYSE:CMRE-PB),(NYSE:CMRE-PC),(NYSE:CMRE-PD), MONACO, July 01, 2025 (GLOBE NEWSWIRE) — Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”) (NYSE: CMRE PR B), US $0.531250 per share on its 8.50% Series C Cumulative Redeemable Perpetual Preferred […]

Abeona Therapeutics(R) Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

(NASDAQ:ABEO), CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in

Digi Power X Reports 45% Month-Over-Month Increase in Cash and Crypto Position with no Long-Term Debt and Reports June 2025 Production Results

(TSX-V:DGHI),(NASDAQ:DGHI),(NASDAQ:DGXX),(TSX-V:DGX),(NASDAQ:SMCI),(NASDAQ:NNE), This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025 MIAMI, July 01, 2025 (GLOBE NEWSWIRE) — Digi Power X Inc. (“Digi Power X” or the “Company“) (Nasdaq: DGXX / TSXV: DGX), an

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target

(NASDAQ:CGTX), PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 'START' Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer's Clinical Trials Consortium (ACTC), with $81

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ(R) MRD Testing into OncoEMR(R)

(NASDAQ:ADPT), SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today

FinWise Bancorp to Host Second Quarter 2025 Earnings Conference Call and Webcast on Thursday, July 24, 2025

(NasdaqGM:FINW), MURRAY, Utah, July 01, 2025 (GLOBE NEWSWIRE) — FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), the parent company of FinWise Bank, today announced that it will report its second quarter 2025 results and host a conference call and webcast after the market close on Thursday, July 24, 2025. Conference Call Information The conference

Sonoco To Report Second Quarter 2025 Results

(NYSE:SON), HARTSVILLE, S.C., July 01, 2025 (GLOBE NEWSWIRE) — Sonoco Products Company (“Sonoco” or the “Company”)(NYSE: SON), a global leader in high-value sustainable packaging, will announce second quarter 2025 results on Wednesday, July 23, 2025, after the market closes. The Company will host a conference call to discuss these results on Thursday, July 24, 2025,

Watsco Declares $3.00 Quarterly Dividend

(NYSE:WSO), MIAMI, July 01, 2025 (GLOBE NEWSWIRE) — Watsco, Inc.'s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $3.00 on each outstanding share of its Common and Class B common stock payable on July 31, 2025 to shareholders of record at the close of business on July 16, 2025. Watsco

Nexxen Announces June 2025 Share Repurchase Program Summary

(NasdaqGM:NEXN), NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced that during June 2025 the Company repurchased 800,000 Ordinary Shares at an average price of $10.45. As of June 30, 2025,

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Active Ingredient Manufacturing Transfer to the U.S. Complete Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active

Scroll to Top